MOLECULAR BIOLOGY OF HTLV-I: BIOLOGICAL SIGNIFICANCE OF VIRAL GENES IN ITS REPLICATION AND LEUKEMOGENESIS NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


MOLECULAR BIOLOGY OF HTLV-I: BIOLOGICAL SIGNIFICANCE OF VIRAL GENES IN ITS REPLICATION AND LEUKEMOGENESIS

Retrovirus Biology and Human Disease. Gallo RC and Wong-Staal F, eds. New York, Marcel Dekker, p. 161-86, 1990.. Unique Identifier : AIDSLINE ICDB/91676223
Yoshida M; Seiki M; Dept. of Viral Oncology, Cancer Inst., Kami-Ikebukuro,; Toshima-ku, Tokyo, Japan


Abstract: Based on results obtained in studies of animal retroviruses, researchers have expected examination of human T-cell leukemia virus type 1 (HTLV-I) and acute T-cell leukemia (ATL) to yield information concerning tumorigenesis in humans. The authors' studies on the molecular biology of HTLV-I are reviewed, with emphasis on the functions of pX and env genes and their significance in ATL development and its prevention. Topics include etiology of ATL, transacting viral function for ATL development, genomic structure and gene products, the envelope gene product (characterization of the product, its functions, and uses of the env protein), pX gene products and the mechanism of their expression, functions of pX proteins, transactivation of interleukin-2 (IL-2) receptor gene, significance of IL-2 receptor gene activation by tax, and a multistep model of ATL progression. Molecular biology studies on HTLV-I have clarified the regulatory mechanism of the viral gene expression and replication and have indicated the possible mechanism involved in the early stage of ATL development. The envelope gene of HTLV-I has been expressed in bacteria as fusion proteins and produced in large quantity. These fusion proteins are useful as diagnostic reagents and vaccine to prevent HTLV-I infection. The extra sequence 'pX' is a self-regulatory sequence that exerts positive and negative controls on viral gene expression. Two genes, tax and rex, are involved in these regulations and their functions have been characterized. The tax gene codes for p40tax, which is a transactivator of transcription of the HTLV-I genome activating an enhancer in the long terminal repeat. The tax also activates the cellular IL-2 receptor alpha (Tac antigen) in certain T-cell lines responding to the 5' regulatory sequences. This activation of the IL-2R gene may account for early events in ATL development. The rex gene codes for p27rex, which is a post-transcriptional regulator required for expression of the gag, pol, and env proteins. The rex increases the levels of unspliced mRNAs. The rex mediates a feedback control of viral gene transcription. Thus, rex makes the viral gene expression transient and the infected cell can escape from host immune response. Two transacting regulatory systems of HTLV-I resemble those of HIV in regulating viral replication, but the functional mechanisms seem to differ. (71 Refs)
Keywords: *Cloning, Molecular Gene Expression Regulation, Leukemic/*PHYSIOLOGY Gene Expression Regulation, Viral/*PHYSIOLOGY Genes, pX/GENETICS Genes, Viral/*GENETICS Human HTLV-I/*GENETICS Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*MICROBIOLOGY Proviruses/GENETICS Receptors, Interleukin-2/GENETICS Transcription, Genetic/GENETICS Virus Replication/*GENETICS MONOGRAPH REVIEW

KWDcloning,moleculargeneexpressionregulation,leukemic/KWDphysiologygeneexpressionregulation,viral/KWDphysiologygenes,px/geneticsgenes,viral/KWDgeneticshumanhtlv-i/KWDgeneticsleukemia-lymphoma,t-cell,acute,htlv-i-associated/KWDmicrobiologyproviruses/geneticsreceptors,interleukin-2/geneticstranscription,genetic/geneticsvirusreplication/KWDgeneticsmonographreview
911130
M91B0830


Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .